Cheng Zou

Xi'an, 710000, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Current Status and Evolution of Immunotherapy in Glioma Management.

Current Status and Evolution of Immunotherapy in Glioma Management.

Journal: International journal of medical sciences
Published: February 05, 2026

CRISPRa-identified transcription factors reprogram glioblastoma into dendritic cell-like cells to elicit systemic antitumor immunity.

CRISPRa-identified transcription factors reprogram glioblastoma into dendritic cell-like cells to elicit systemic antitumor immunity.

Journal: Cell reports. Medicine
Published: November 28, 2025

Targeted degradation of CD24 by a transferrin receptor-engaging bispecific degrader enhances antitumor immunity.

Targeted degradation of CD24 by a transferrin receptor-engaging bispecific degrader enhances antitumor immunity.

Journal: Biochemical pharmacology
Published: October 14, 2025

CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation.

CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation.

Journal: MedScience
Published: September 03, 2025

Targeting TRIM25 as a therapeutic strategy to enhance ferroptosis in glioblastoma cells.

Targeting TRIM25 as a therapeutic strategy to enhance ferroptosis in glioblastoma cells.

Journal: Journal of nanobiotechnology
Published: August 27, 2025

Biomimetic Dendritic Cell-Based Nanovaccines for Reprogramming the Immune Microenvironment to Boost Tumor Immunotherapy.

Biomimetic Dendritic Cell-Based Nanovaccines for Reprogramming the Immune Microenvironment to Boost Tumor Immunotherapy.

Journal: ACS nano
Published: December 03, 2024

Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade.

Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade.

Journal: Journal of nanobiotechnology
Published: October 30, 2024

Targeting GDF15 to enhance immunotherapy efficacy in glioblastoma through tumor microenvironment-responsive CRISPR-Cas9 nanoparticles.

Targeting GDF15 to enhance immunotherapy efficacy in glioblastoma through tumor microenvironment-responsive CRISPR-Cas9 nanoparticles.

Journal: Journal of nanobiotechnology
Published: October 14, 2024

Biomimetic Macrophage Membrane-Camouflaged Nanoparticles Induce Ferroptosis by Promoting Mitochondrial Damage in Glioblastoma.

Biomimetic Macrophage Membrane-Camouflaged Nanoparticles Induce Ferroptosis by Promoting Mitochondrial Damage in Glioblastoma.

Journal: ACS nano
Published: November 22, 2023

Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma.

Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma.

Journal: ACS nano
Published: August 30, 2023
Showing 1-10 of 10

Last Updated: 09/26/2026